Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $5240.0.

  • China SXT Pharmaceuticals' Current Deferred Revenue rose 29581.46% to $5240.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5240.0, marking a year-over-year increase of 29581.46%. This contributed to the annual value of $58627.0 for FY2025, which is 6875.98% down from last year.
  • China SXT Pharmaceuticals' Current Deferred Revenue amounted to $5240.0 in Q3 2025, which was up 29581.46% from $58627.0 recorded in Q1 2025.
  • China SXT Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $257449.0 during Q1 2021, with a 5-year trough of -$42994.0 in Q3 2021.
  • In the last 5 years, China SXT Pharmaceuticals' Current Deferred Revenue had a median value of $46906.0 in 2023 and averaged $73733.3.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 11977.54% in 2021, then surged by 96598.57% in 2023.
  • China SXT Pharmaceuticals' Current Deferred Revenue (Quarter) stood at -$42994.0 in 2021, then soared by 90.55% to -$4063.0 in 2022, then skyrocketed by 965.99% to $35185.0 in 2023, then tumbled by 107.61% to -$2676.0 in 2024, then surged by 295.81% to $5240.0 in 2025.
  • Its Current Deferred Revenue was $5240.0 in Q3 2025, compared to $58627.0 in Q1 2025 and -$2676.0 in Q3 2024.